Sep 21 2016

Actavis Pharma, Inc

#actavis pharma manufacturing # Actavis Pharma, Inc. Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page …

Sep 17 2016

Dublin-based Actavis to buy Forest Labs for $25 billion

#forest pharma # Dublin-based Actavis to buy Forest Labs for $25 billion Actavis. the world’s second-largest generic-drug maker by market value, is to buy Forest Laboratories in a cash and stock deal valued at about $25 billion. Actavis will pay the equivalent of $89.48 per share, representing a premium of 25 per cent to Forest’s Friday close. The offer comprises $26.04 in cash and 0.3306 Actavis shares for every Forest share. Forest had a market value of $19.3 billion at the close of trading last Friday. Dublin-headquartered Actavis was the most active buyer of drug companies over the past three …